Key drug regulatory changes take effect in Russia
This article was originally published in SRA
Pharma firms in Russia are facing major regulatory changes and new legal responsibilities despite a last-minute attempt by the authorities to postpone the provisions until next year so as to allow more time to prepare for their introduction. Among the measures are shorter approval times for new medicines, and new rules on biologics, pharmacovigilance and product interchangeability.
Register for our free email digests: